Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings.

Date publication

novembre 2020

Journal

The oncologist

Auteurs

Membres identifiés du Cancéropôle Est :
Dr EBERST Lauriane

Tous les auteurs :
Saleh M, Cassier PA, Eberst L, Naik G, Morris VK, Pant S, Terret C, Gao L, Long A, Mao H, McNeely S, Wagner EK, Carlesi RM, Fu S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32537847

Résumé

The combination of the antivascular endothelial growth factor receptor 2 monoclonal antibody, ramucirumab, and the type II MET kinase inhibitor, merestinib, is tolerable. Preliminary efficacy data suggest that the combination may provide clinical benefit to patients with metastatic colorectal cancer (mCRC). Further development of this combination would likely necessitate the identification of subsets of patients with mCRC where the clinical benefit is of clinical relevance.

Mots clés

Adolescent, Adult, Aged, Antibodies, Monoclonal, adverse effects, Antibodies, Monoclonal, Humanized, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Colorectal Neoplasms, drug therapy, Female, Humans, Male, Middle Aged, Young Adult

Référence

Oncologist. 2020 11;25(11):e1628-e1639